
P R E S S R E L E A S E

Ypsomed to start supply of insulin pen developed on the YpsoPen® platform to Ukraine

Burgdorf, 11 February 2016, 7:00 – The reusable and affordable YpsoPen® is becoming more and more popular. In the coming weeks, it will be supplied to Ukraine. The pharma company Indar, a private joint-stock company (PrJSC), is launching the insulin pen developed in Switzerland.

The Kiev-based company will use id Pen, an insulin pen developed on the YpsoPen® platform, to administer its Humodar human insulin. PrJSC Indar has invested in the research and development of drugs for over 15 years, focusing particularly on insulin. The foundation of PrJSC Indar is based on a resolution of the Ukraine Cabinet of Ministers adopted in 1997 that stipulates that insulin should be manufactured locally. Three years later, PrJSC Indar had already launched its Humodar human insulin on the market. Now it is adding the user-friendly id Pen based on the YpsoPen® platform to its product portfolio.

For further information, please contact Benjamin Overney, Head of Investor & Public Relations at Ypsomed Holding AG, by phone at +41 34 424 41 59 or by email (benjamin.overney@ypsomed.com).

About the Ypsomed Group

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, autoimmune diseases, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading respectively. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,200 employees.